精準免疫腫瘤學市場規模、佔有率、成長分析、按癌症類型、按治療類型、按生物標記、按最終用途、按地區 - 行業預測，2025-2032 年

2023年全球精準免疫腫瘤市場規模為606.5億美元，從2024年的672億美元成長到2032年的1,526.5億美元，預測期（2025-2032）預計複合年成長率為10.8%。

精準免疫腫瘤學正迅速成為癌症治療的開創性方法，重點在於考慮患者遺傳特徵、腫瘤特徵和免疫反應的個人化治療。與傳統治療方法相比，這種個人化策略不僅提高了治療效果，而且還最大限度地減少了副作用，為長期緩解帶來了希望。先進的診斷在識別癌細胞上的特異性基因突變和蛋白質以及實現有針對性的干涉方面發揮關鍵作用。臨床試驗已經顯示出有希望的結果，特別是在患有抗治療性癌症的患者中，並且已經顯示出顯著的患者反應。隨著製藥公司意識到精準免疫腫瘤學的變革潛力，在這一領域進行了大量投資，這標誌著癌症治療發展的一個重要里程碑，並凸顯了市場的光明前景。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 宏觀經濟指標
• 價值鏈分析
• 價格分析
• 技術分析
• 專利分析
• 研發線產品分析
• 案例研究分析

精準免疫腫瘤學市場規模：依癌症類型分類

• 市場概況
• 肺癌
• 乳癌
• 攝護腺癌
• 惡性黑色素瘤
• 其他

按治療類型分類的精準免疫腫瘤學市場規模

• 市場概況
• 查核點抑制劑
• CAR-T細胞療法
• 癌症疫苗
• 其他

精準免疫腫瘤學市場規模：依生物標記分類

• 市場概況
• PD-L1
• BRCA
• KRAS
• EGFR
• 其他

按最終用途分類的精準免疫腫瘤學市場規模

• 市場概況
• 醫院
• 診所
• 調查機構
• 其他

精準免疫腫瘤學市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Adaptimmune Therapeutics plc（UK）
• Agenus Inc.（US）
• Amgen Inc.（US）
• AstraZeneca plc（UK）
• Bristol Myers Squibb Company（US）
• Celgene Corporation（US）
• Eli Lilly and Company（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Gilead Sciences, Inc.（US）
• GlaxoSmithKline plc（UK）
• Iovance Biotherapeutics, Inc.（US）
• Juno Therapeutics, Inc.（US）
• Kite Pharma, Inc.（US）
• Merck & Co., Inc.（US）
• Neon Therapeutics, Inc.（US）
• Novartis AG（Switzerland）
• Pfizer Inc.（US）
• Sanofi SA（France）
• Seattle Genetics, Inc.（US）
• Takeda Pharmaceutical Company Limited（Japan）

結論和建議

Global Precision Immuno-Oncology Market size was valued at USD 60.65 billion in 2023 and is poised to grow from USD 67.20 billion in 2024 to USD 152.65 billion by 2032, growing at a CAGR of 10.8% during the forecast period (2025-2032).

Precision immuno-oncology is swiftly gaining traction as a pioneering approach in cancer treatment, focusing on tailored therapies that consider patients' genetic profiles, tumor characteristics, and immune responses. This personalized strategy not only enhances treatment efficacy but also minimizes side effects compared to conventional therapies, offering hope for long-term remissions. Advanced diagnostics play a crucial role in identifying unique genetic mutations and proteins on cancer cells, enabling targeted interventions. Clinical trials have demonstrated encouraging results, particularly in patients with treatment-resistant cancers, showcasing remarkable patient responses. The sector is witnessing substantial investment as pharmaceutical companies recognize the transformative potential of precision immuno-oncology, marking a significant milestone in the evolution of cancer care and highlighting its promising future in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Immuno-Oncology Market Segmental Analysis

Global Precision Immuno-Oncology Market is segmented by cancer type, treatment type, biomarker, end use and region. Based on cancer type, the market is segmented into lung cancer, breast cancer, prostate cancer, melanoma and others. Based on treatment type, the market is segmented into checkpoint inhibitors, Car T Cell Therapy, cancer vaccines and others. Based on biomarker, the market is segmented into PD-L1, BRCA, KRAS, EGFR and others. Based on end use, the market is segmented into hospital, clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market is witnessing significant growth driven by the rising incidence of cancer worldwide. As cancer remains a pressing health issue, the need for advanced treatment options is becoming increasingly urgent. Traditional therapies like chemotherapy and radiation often have severe limitations and side effects, leading to a push for more innovative solutions. Precision immuno-oncology stands out by harnessing the body's immune system to combat cancer effectively. This tailored approach enables the development of targeted therapies based on individual genetic profiles, tumor characteristics, and immune responses, potentially enhancing treatment efficacy while minimizing adverse effects, thus propelling market demand.

Restraints in the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market faces significant challenges primarily due to the high costs associated with these advanced therapies. Unlike traditional cancer treatments, precision immuno-oncology offers a personalized approach, which inherently involves complex and expensive methodologies. This heightened expense can restrict patient access, particularly for those in developing nations where healthcare resources are scarce. Factors such as exorbitant research and development expenditures, the requirement for specialized equipment, and the processes involved in biomarker testing further escalate costs. The unique treatment plans tailored for individual patients add another layer of expense, creating disparities in access to effective cancer care, especially for individuals from low- and middle-income regions, thereby exacerbating existing inequities in cancer treatment and outcomes.

Market Trends of the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market is witnessing significant growth driven by the increasing adoption of combination therapies that integrate immunotherapy with traditional treatments like chemotherapy and radiation. This trend is rooted in the rising awareness of the enhanced treatment efficacy and the potential to combat drug resistance inherent in singular therapies. As research continues to yield promising results-especially in complex cancers such as lung cancer and melanoma-clinicians are increasingly leveraging these multi-faceted treatment approaches to improve patient outcomes. Furthermore, advancements in biomarker identification and personalized medicine are expected to further propel market expansion, catering to a more tailored cancer treatment landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Pipeline Product Analysis
• Case Study Analysis

Global Precision Immuno-Oncology Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Melanoma
• Others

Global Precision Immuno-Oncology Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Checkpoint Inhibitors
• Car T Cell Therapy
• Cancer Vaccines
• Others

Global Precision Immuno-Oncology Market Size by Biomarker & CAGR (2025-2032)

• Market Overview
• PD-L1
• BRCA
• KRAS
• EGFR
• Others

Global Precision Immuno-Oncology Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospital
• Clinics
• Research Institutes
• Others

Global Precision Immuno-Oncology Market Size & CAGR (2025-2032)

• North America (Cancer Type, Treatment Type, Biomarker, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment Type, Biomarker, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment Type, Biomarker, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment Type, Biomarker, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment Type, Biomarker, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Adaptimmune Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neon Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seattle Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations